SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Munoz N,Bosch FX,Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 20:111: 278285.
  • 2
    Dunne EF,Datta SD,Markowitz L. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the United States. Cancer. 2008; 113( 10 suppl): 29953003.
  • 3
    Hildesheim A,Herrero R,Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298: 743753.
  • 4
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 19151927.
  • 5
    Garland SM,Hernandez-Avila M,Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 19281943.
  • 6
    Saslow D,Castle PE,Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 728.
  • 7
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H,Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 124.
  • 8
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007; 111: 145153.
  • 9
    Kovacic MB,Castle PE,Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006; 66: 1011210119.
  • 10
    Paavonen J,Jenkins D,Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 21612170.
  • 11
    Davey DD,Neal MH,Wilbur DC,Colgan TJ,Styer PE,Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004; 128: 1224129.
  • 12
    Khan MJ,Castle PE,Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 20:97: 1072109.
  • 13
    Plummer M,Schiffman M,Castle PE,Maucort-Boulch D,Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007; 195: 1582159.
  • 14
    Rodriguez AC,Schiffman M,Herrero R, et al; Proyecto Epidemiologico Guanacastle Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008: 100: 513517.
  • 15
    Stoler MH,Castle PE,Solomon D,Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 13.
  • 16
    Jeronimo J,Massad LS,Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. 2007; 197: 4748.
  • 17
    Lorincz AT,Reid R,Jenson AB,Greenberg MD,Lancaster W,Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992; 79: 328337.
  • 18
    Smith JS,Lindsay L,Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121: 621632.
  • 19
    Castle PE,Stoler MH,Solomon D,Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007; 127: 805815.
  • 20
    Kyrgiou M,Koliopoulos G,Martin-Hirsch P,Arbyn M,Prendiville W,Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006; 367: 489498.
  • 21
    Saraiya M,Goodman MT,Datta SD,Chen VW,Wingo PA. Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role [commentary]. Cancer. 2008; 113( 10 suppl): 30473057.
  • 22
    Goldhaber-Fiebert JD,Stout NK,Salomon JA,Kuntz KM,Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008; 100: 308320.
  • 23
    Saslow D,Runowicz CD,Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342362.
  • 24
    Wright TCJr,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 346355.
  • 25
    Davey E,d'Assuncao J,Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007; 335: 3131.
  • 26
    Wentzensen N,von Knebel DM. Biomarkers in cervical cancer screening. Dis Markers. 2007; 23: 315330.
  • 27
    Naucler P,Ryd W,Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357: 15891597.
  • 28
    Mayrand MH,Duarte-Franco E,Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 15791588.
  • 29
    Ronco G,Giorgi-Rossi P,Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment fora randomised controlled trial. Lancet Oncol. 2006; 7: 547555.
  • 30
    Bulkmans NW,Berkhof J,Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370: 17641772.
  • 31
    Ronco G,Segnan N,Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98: 765774.